SecSonar.com

Autolus Therapeutics plc (AUTL)

Autolus Therapeutics plc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Autolus Therapeutics plc (AUTL) is a Biotechnology company based in GB with a market capitalization of $492.4M. Revenue grew 646.7% year-over-year and free cash flow was negative at -$302.7M. This page tracks AUTL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

GB · 647 employees · IPO Jun 22, 2018

Valuation

Valuation & price

$1.69 · as of May 26, 2026 · -37.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.76

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.68$1.95$1.21Jul 25Dec 25Jul 26Jul 7, 25$2.26Jul 9, 25$2.47Jul 11, 25$2.47Jul 15, 25$2.49Jul 17, 25$2.42Jul 21, 25$2.43Jul 23, 25$2.68Jul 25, 25$2.52Jul 29, 25$2.42Jul 31, 25$2.40Aug 4, 25$2.38Aug 6, 25$2.31Aug 11, 25$2.47Aug 13, 25$1.84Aug 15, 25$1.78Aug 19, 25$1.79Aug 21, 25$1.75Aug 25, 25$1.60Aug 27, 25$1.57Aug 29, 25$1.50Sep 3, 25$1.44Sep 5, 25$1.46Sep 9, 25$1.37Sep 11, 25$1.43Sep 16, 25$1.32Sep 18, 25$1.36Sep 22, 25$1.38Sep 24, 25$1.56Sep 26, 25$1.56Sep 30, 25$1.63Oct 2, 25$1.61Oct 6, 25$1.56Oct 8, 25$1.76Oct 10, 25$1.66Oct 14, 25$1.62Oct 16, 25$1.68Oct 21, 25$1.63Oct 23, 25$1.50Oct 27, 25$1.65Oct 29, 25$1.46Oct 31, 25$1.55Nov 4, 25$1.41Nov 6, 25$1.36Nov 10, 25$1.32Nov 12, 25$1.36Nov 14, 25$1.37Nov 18, 25$1.29Nov 20, 25$1.23Nov 25, 25$1.39Nov 28, 25$1.41Dec 2, 25$1.34Dec 4, 25$1.57Dec 8, 25$1.59Dec 10, 25$1.53Dec 12, 25$1.61Dec 16, 25$1.60Dec 18, 25$1.57Dec 22, 25$1.73Dec 24, 25$1.68Dec 29, 25$1.87Jan 2, 26$1.87Jan 6, 26$2.00Jan 8, 26$1.91Jan 12, 26$1.50Jan 14, 26$1.42Jan 16, 26$1.38Jan 21, 26$1.47Jan 23, 26$1.46Jan 27, 26$1.42Jan 29, 26$1.43Feb 2, 26$1.38Feb 4, 26$1.38Feb 9, 26$1.46Feb 11, 26$1.43Feb 13, 26$1.40Feb 18, 26$1.56Feb 20, 26$1.67Feb 24, 26$1.82Feb 26, 26$1.77Mar 2, 26$1.67Mar 4, 26$1.63Mar 6, 26$1.51Mar 10, 26$1.60Mar 12, 26$1.46Mar 17, 26$1.51Mar 19, 26$1.43Mar 23, 26$1.40Mar 25, 26$1.33Mar 27, 26$1.21Mar 31, 26$1.38Apr 2, 26$1.41Apr 7, 26$1.36Apr 9, 26$1.47Apr 13, 26$1.47Apr 15, 26$1.49Apr 17, 26$1.60Apr 22, 26$1.60Apr 24, 26$1.44Apr 28, 26$1.48Apr 30, 26$1.41May 4, 26$1.57May 6, 26$1.70May 8, 26$1.57May 12, 26$1.60May 14, 26$1.59May 18, 26$1.80May 20, 26$1.62May 22, 26$1.70May 28, 26$1.77Jun 1, 26$1.84Jun 3, 26$1.62Jun 5, 26$1.53Jun 9, 26$1.46Jun 11, 26$1.56Jun 15, 26$1.50Jun 17, 26$1.53Jun 22, 26$1.49Jun 24, 26$1.59Jun 26, 26$1.61Jul 2, 26$1.58
$1.2152-week range$2.68
Loading valuation history…

Fundamentals

Key fundamentals

$492.4M

Market cap

646.7%

Revenue growth (YoY)

-27.8%

Gross margin

-$302.7M

Free cash flow (USD)

$50.9M

Net debt

4.3%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.2MFY 2017$1.7MFY 2018$1.0MFY 2019$2.9MFY 2020$1.7MFY 2021$1.5MFY 2022$6.2MFY 2023$1.7MFY 2024$10.1MFY 2025$75.6M
$1.2M$75.6M

Free cash flow by year

2016 → 2025

FY 2016$-11.7MFY 2017$-19.2MFY 2018$-34.6MFY 2019$-120.2MFY 2020$-132.4MFY 2021$-126.7MFY 2022$-123.1MFY 2023$-156.6MFY 2024$-241.1MFY 2025$-302.7M
-$11.7M-$302.7M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024-1293.5%FY 2025-27.8%
100.0%-27.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 14, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual General Meeting ResultsJun 29, 2026Filing
  • 8-K eventAnnual Report FiledJun 9, 2026Filing
  • 8-K eventEarnings ReleaseMay 14, 2026Filing
  • Quarterly report10-Q FiledMay 14, 2026Filing
  • 8-K eventWorkforce ReductionApr 29, 2026Filing
  • 8-K eventAccounting Firm ChangeApr 16, 2026Filing
  • FinancingSecurities RegistrationApr 13, 2026Filing
  • FinancingSecurities RegistrationApr 13, 2026Filing
  • 8-K eventInvestor Event AnnouncementApr 8, 2026Filing

Questions

Frequently asked questions

What is Autolus Therapeutics plc's market cap?

Autolus Therapeutics plc (AUTL) has a market capitalization of $492.4M.

What is AUTL's P/E ratio?

A meaningful P/E ratio is not available for AUTL — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is AUTL's price-to-book (P/B) ratio?

AUTL trades at 2.76 times book value per share.

Are insiders buying AUTL stock?

SEC Form 4 filings show no open-market insider buys at Autolus Therapeutics plc in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

CTNM

Contineum Therapeutics, Inc. Class A Common Stock

$499.1M

EBS

Emergent BioSolutions Inc.

$478.8M

FDMT

4D Molecular Therapeutics, Inc.

$506.6M

OCGN

Ocugen, Inc.

$470M

XOMA

XOMA Royalty Corp.

$523.3M

ALLO

Allogene Therapeutics, Inc.

$524.6M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.